EDWARDS LIFESCIENCES CORP (EW) Stock Fundamental Analysis

USA • New York Stock Exchange • NYSE:EW • US28176E1082

78.71 USD
+0.61 (+0.78%)
At close: Feb 6, 2026
78.5 USD
-0.21 (-0.27%)
After Hours: 2/6/2026, 8:04:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

7

Taking everything into account, EW scores 7 out of 10 in our fundamental rating. EW was compared to 186 industry peers in the Health Care Equipment & Supplies industry. EW has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. EW has a decent growth rate and is not valued too expensively. These ratings would make EW suitable for quality investing!


Dividend Valuation Growth Profitability Health

9

1. Profitability

1.1 Basic Checks

  • In the past year EW was profitable.
  • EW had a positive operating cash flow in the past year.
  • In the past 5 years EW has always been profitable.
  • EW had a positive operating cash flow in each of the past 5 years.
EW Yearly Net Income VS EBIT VS OCF VS FCFEW Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

1.2 Ratios

  • With an excellent Return On Assets value of 10.31%, EW belongs to the best of the industry, outperforming 94.62% of the companies in the same industry.
  • EW has a better Return On Equity (13.40%) than 89.25% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 12.50%, EW belongs to the top of the industry, outperforming 93.01% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for EW is significantly above the industry average of 8.80%.
Industry RankSector Rank
ROA 10.31%
ROE 13.4%
ROIC 12.5%
ROA(3y)21.77%
ROA(5y)18.87%
ROE(3y)29.68%
ROE(5y)26.56%
ROIC(3y)15.82%
ROIC(5y)17.27%
EW Yearly ROA, ROE, ROICEW Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

1.3 Margins

  • EW's Profit Margin of 23.25% is amongst the best of the industry. EW outperforms 95.16% of its industry peers.
  • In the last couple of years the Profit Margin of EW has grown nicely.
  • EW's Operating Margin of 27.73% is amongst the best of the industry. EW outperforms 96.24% of its industry peers.
  • EW's Operating Margin has been stable in the last couple of years.
  • EW has a better Gross Margin (78.19%) than 90.86% of its industry peers.
  • EW's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 27.73%
PM (TTM) 23.25%
GM 78.19%
OM growth 3Y-5.94%
OM growth 5Y-1.04%
PM growth 3Y38.76%
PM growth 5Y26.09%
GM growth 3Y1.43%
GM growth 5Y1.33%
EW Yearly Profit, Operating, Gross MarginsEW Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

9

2. Health

2.1 Basic Checks

  • EW has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • The number of shares outstanding for EW has been reduced compared to 1 year ago.
  • The number of shares outstanding for EW has been reduced compared to 5 years ago.
  • Compared to 1 year ago, EW has an improved debt to assets ratio.
EW Yearly Shares OutstandingEW Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M
EW Yearly Total Debt VS Total AssetsEW Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B 10B

2.2 Solvency

  • EW has an Altman-Z score of 11.71. This indicates that EW is financially healthy and has little risk of bankruptcy at the moment.
  • EW has a better Altman-Z score (11.71) than 90.86% of its industry peers.
  • EW has a debt to FCF ratio of 0.75. This is a very positive value and a sign of high solvency as it would only need 0.75 years to pay back of all of its debts.
  • EW has a Debt to FCF ratio of 0.75. This is amongst the best in the industry. EW outperforms 90.86% of its industry peers.
  • EW has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.
  • With a decent Debt to Equity ratio value of 0.06, EW is doing good in the industry, outperforming 67.74% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF 0.75
Altman-Z 11.71
ROIC/WACC1.24
WACC10.05%
EW Yearly LT Debt VS Equity VS FCFEW Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

2.3 Liquidity

  • A Current Ratio of 4.00 indicates that EW has no problem at all paying its short term obligations.
  • With a decent Current ratio value of 4.00, EW is doing good in the industry, outperforming 68.28% of the companies in the same industry.
  • A Quick Ratio of 3.29 indicates that EW has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 3.29, EW is in the better half of the industry, outperforming 68.28% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4
Quick Ratio 3.29
EW Yearly Current Assets VS Current LiabilitesEW Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • EW shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -3.75%.
  • The Earnings Per Share has been growing slightly by 7.13% on average over the past years.
  • Looking at the last year, EW shows a small growth in Revenue. The Revenue has grown by 4.67% in the last year.
  • Measured over the past years, EW shows a small growth in Revenue. The Revenue has been growing by 4.58% on average per year.
EPS 1Y (TTM)-3.75%
EPS 3Y5.52%
EPS 5Y7.13%
EPS Q2Q%0%
Revenue 1Y (TTM)4.67%
Revenue growth 3Y1.3%
Revenue growth 5Y4.58%
Sales Q2Q%14.67%

3.2 Future

  • EW is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 9.40% yearly.
  • EW is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.47% yearly.
EPS Next Y1.27%
EPS Next 2Y6.53%
EPS Next 3Y7.87%
EPS Next 5Y9.4%
Revenue Next Year4.63%
Revenue Next 2Y7.15%
Revenue Next 3Y8.06%
Revenue Next 5Y8.47%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
EW Yearly Revenue VS EstimatesEW Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2B 4B 6B 8B
EW Yearly EPS VS EstimatesEW Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1 2 3 4

More info and screens

Find the best growth stocksShow best growing peers

4

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 30.63, which means the current valuation is very expensive for EW.
  • Based on the Price/Earnings ratio, EW is valued a bit cheaper than the industry average as 74.73% of the companies are valued more expensively.
  • The average S&P500 Price/Earnings ratio is at 27.93. EW is around the same levels.
  • With a Price/Forward Earnings ratio of 26.47, EW can be considered very expensive at the moment.
  • Based on the Price/Forward Earnings ratio, EW is valued a bit cheaper than the industry average as 74.73% of the companies are valued more expensively.
  • EW's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 27.77.
Industry RankSector Rank
PE 30.63
Fwd PE 26.47
EW Price Earnings VS Forward Price EarningsEW Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, EW is valued a bit cheaper than the industry average as 73.66% of the companies are valued more expensively.
  • Based on the Price/Free Cash Flow ratio, EW is valued a bit cheaper than 72.04% of the companies in the same industry.
Industry RankSector Rank
P/FCF 57.12
EV/EBITDA 23.08
EW Per share dataEW EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates EW does not grow enough to justify the current Price/Earnings ratio.
  • The excellent profitability rating of EW may justify a higher PE ratio.
PEG (NY)24.09
PEG (5Y)4.3
EPS Next 2Y6.53%
EPS Next 3Y7.87%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for EW!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

EDWARDS LIFESCIENCES CORP

NYSE:EW (2/6/2026, 8:04:00 PM)

After market: 78.5 -0.21 (-0.27%)

78.71

+0.61 (+0.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)10-30
Earnings (Next)02-10
Inst Owners89.94%
Inst Owner Change-2.11%
Ins Owners0.11%
Ins Owner Change-1%
Market Cap45.68B
Revenue(TTM)5.88B
Net Income(TTM)1.37B
Analysts79.52
Price Target98.01 (24.52%)
Short Float %1.38%
Short Ratio2.35
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.01%
Min EPS beat(2)4.4%
Max EPS beat(2)9.63%
EPS beat(4)4
Avg EPS beat(4)5.38%
Min EPS beat(4)3.4%
Max EPS beat(4)9.63%
EPS beat(8)5
Avg EPS beat(8)2.27%
EPS beat(12)6
Avg EPS beat(12)1.21%
EPS beat(16)7
Avg EPS beat(16)-0.18%
Revenue beat(2)1
Avg Revenue beat(2)0.37%
Min Revenue beat(2)-0.12%
Max Revenue beat(2)0.85%
Revenue beat(4)1
Avg Revenue beat(4)-0.56%
Min Revenue beat(4)-2.1%
Max Revenue beat(4)0.85%
Revenue beat(8)1
Avg Revenue beat(8)-2.7%
Revenue beat(12)2
Avg Revenue beat(12)-2.12%
Revenue beat(16)2
Avg Revenue beat(16)-2.48%
PT rev (1m)0.92%
PT rev (3m)9.17%
EPS NQ rev (1m)-0.25%
EPS NQ rev (3m)0.74%
EPS NY rev (1m)-0.24%
EPS NY rev (3m)2.88%
Revenue NQ rev (1m)0.19%
Revenue NQ rev (3m)0.31%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.91%
Valuation
Industry RankSector Rank
PE 30.63
Fwd PE 26.47
P/S 7.76
P/FCF 57.12
P/OCF 44.92
P/B 4.48
P/tB 6.25
EV/EBITDA 23.08
EPS(TTM)2.57
EY3.27%
EPS(NY)2.97
Fwd EY3.78%
FCF(TTM)1.38
FCFY1.75%
OCF(TTM)1.75
OCFY2.23%
SpS10.14
BVpS17.59
TBVpS12.59
PEG (NY)24.09
PEG (5Y)4.3
Graham Number31.89
Profitability
Industry RankSector Rank
ROA 10.31%
ROE 13.4%
ROCE 13.97%
ROIC 12.5%
ROICexc 18.63%
ROICexgc 29.56%
OM 27.73%
PM (TTM) 23.25%
GM 78.19%
FCFM 13.59%
ROA(3y)21.77%
ROA(5y)18.87%
ROE(3y)29.68%
ROE(5y)26.56%
ROIC(3y)15.82%
ROIC(5y)17.27%
ROICexc(3y)20.51%
ROICexc(5y)22.13%
ROICexgc(3y)29.09%
ROICexgc(5y)31.03%
ROCE(3y)17.66%
ROCE(5y)19.29%
ROICexgc growth 3Y-5.47%
ROICexgc growth 5Y-8.01%
ROICexc growth 3Y-11.82%
ROICexc growth 5Y-8.6%
OM growth 3Y-5.94%
OM growth 5Y-1.04%
PM growth 3Y38.76%
PM growth 5Y26.09%
GM growth 3Y1.43%
GM growth 5Y1.33%
F-Score6
Asset Turnover0.44
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF 0.75
Debt/EBITDA 0.33
Cap/Depr 138.79%
Cap/Sales 3.69%
Interest Coverage 250
Cash Conversion 56.86%
Profit Quality 58.45%
Current Ratio 4
Quick Ratio 3.29
Altman-Z 11.71
F-Score6
WACC10.05%
ROIC/WACC1.24
Cap/Depr(3y)185.14%
Cap/Depr(5y)236.01%
Cap/Sales(3y)5.48%
Cap/Sales(5y)6.41%
Profit Quality(3y)37.92%
Profit Quality(5y)57.13%
High Growth Momentum
Growth
EPS 1Y (TTM)-3.75%
EPS 3Y5.52%
EPS 5Y7.13%
EPS Q2Q%0%
EPS Next Y1.27%
EPS Next 2Y6.53%
EPS Next 3Y7.87%
EPS Next 5Y9.4%
Revenue 1Y (TTM)4.67%
Revenue growth 3Y1.3%
Revenue growth 5Y4.58%
Sales Q2Q%14.67%
Revenue Next Year4.63%
Revenue Next 2Y7.15%
Revenue Next 3Y8.06%
Revenue Next 5Y8.47%
EBIT growth 1Y4.68%
EBIT growth 3Y-4.72%
EBIT growth 5Y3.49%
EBIT Next Year13.12%
EBIT Next 3Y12.54%
EBIT Next 5Y12.3%
FCF growth 1Y1.45%
FCF growth 3Y-42.99%
FCF growth 5Y-22.01%
OCF growth 1Y-2.42%
OCF growth 3Y-32.1%
OCF growth 5Y-14.39%

EDWARDS LIFESCIENCES CORP / EW FAQ

What is the fundamental rating for EW stock?

ChartMill assigns a fundamental rating of 7 / 10 to EW.


What is the valuation status for EW stock?

ChartMill assigns a valuation rating of 4 / 10 to EDWARDS LIFESCIENCES CORP (EW). This can be considered as Fairly Valued.


How profitable is EDWARDS LIFESCIENCES CORP (EW) stock?

EDWARDS LIFESCIENCES CORP (EW) has a profitability rating of 9 / 10.


What is the earnings growth outlook for EDWARDS LIFESCIENCES CORP?

The Earnings per Share (EPS) of EDWARDS LIFESCIENCES CORP (EW) is expected to grow by 1.27% in the next year.